HUTCHMED (China) stock trades below USD 14.87 consensus target

Published on 10/17/2026 at 19:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 52-week range was USD 9.77 to USD 16.33 on October 16, 2026. HUTCHMED (China) stock costs USD 14.05 on October 16, 2026, up 0.79 percent on Nasdaq.

Analyst target and latest results

MarketBeat reported a six-brokerage consensus target of USD 14.87 on October 13, 2026.
Second-quarter revenue was USD 139.14 million versus USD 304.16 million expected.
HUTCHMED (China) stock cost USD 14.05 at Nasdaq on October 16, 2026 at 4:00 p.m. ET, up 0.79 percent on the day.
The trailing price-to-earnings ratio was 153.46 as of October 16, 2026.

HCM, US44842L1035, Illustration mit AI erstellt.

HUTCHMED (China) stock trades below a USD 14.87 consensus target after MarketBeat reported the six-brokerage average on October 13, 2026. The target stands 5.84 percent above the latest Nasdaq price. HUTCHMED (China) stock was last at USD 14.05 on October 16, 2026 at 4:00 p.m. ET, up 0.79 percent from the Nasdaq prior close of USD 13.94.

Revenue missed expectations

The latest quarterly result gives the target a more demanding operating backdrop. HUTCHMED reported revenue of USD 139.14 million for the second quarter of 2026, against a consensus estimate of USD 304.16 million, according to MarketBeat. The same report said earnings per share were USD 0.05 versus USD 0.14 expected. That revenue gap is the key counterweight to the above-market consensus target.

Stock sits within its range

The Nasdaq price was 14.38 percent below the 52-week high of USD 16.33 and 43.81 percent above the 52-week low of USD 9.77 on October 16, 2026. The latest quotation was also above the 50-day moving average of USD 13.22 and the 200-day moving average of USD 12.65 cited by MarketBeat. The positioning leaves the stock closer to its yearly high than its yearly low, while the daily move stayed below 1.00 percent.

Valuation in the latest quarter

HUTCHMED had a market capitalization of USD 2.5 billion and a trailing price-to-earnings ratio of 153.46 as of October 16, 2026. Its second-quarter net income was USD 1.73 million, while operating profit was USD 434,500 for the same period. The figures describe a company with positive reported earnings but a valuation that remains highly sensitive to future drug sales.

Comparison with peers

HUTCHMED (Nasdaq, USD): plus 0.79 percent, P/E 153.46, market capitalization USD 2.5 billion

AstraZeneca (Nasdaq, USD): minus 0.76 percent, P/E 24.83, market capitalization USD 256.5 billion

GSK (NYSE, USD): plus 1.00 percent, P/E 15.65, market capitalization USD 99.2 billion

Trading context

The comparison shows how different HUTCHMED's valuation profile is from larger profitable drugmakers. AstraZeneca's market value was more than 100 times larger, while GSK traded on a much lower earnings multiple on October 16, 2026. HUTCHMED's price therefore remains tied more closely to clinical progress and commercial expansion than to current earnings alone.

HUTCHMED (China) Limited is a biopharmaceutical company focused on targeted and immune-based cancer treatments. Its Nasdaq listing uses the ticker HCM, and the company also maintains listings in Hong Kong and London. The next investor-relevant calendar item is the company's presentation of lung cancer data on October 25, 2026, as listed on its shareholder information page.

The stock was last at USD 14.05 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, up 0.79 percent versus the Nasdaq prior close of October 15, 2026 at USD 13.94.